Brown Advisory Inc. Sells 17,723 Shares of Insulet Corporation (NASDAQ:PODD)

Brown Advisory Inc. cut its stake in shares of Insulet Corporation (NASDAQ:PODD - Free Report) by 32.6% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 36,595 shares of the medical instruments supplier's stock after selling 17,723 shares during the period. Brown Advisory Inc. owned 0.05% of Insulet worth $9,610,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. Itau Unibanco Holding S.A. acquired a new position in Insulet during the fourth quarter valued at approximately $42,000. Golden State Wealth Management LLC boosted its position in Insulet by 553.1% during the first quarter. Golden State Wealth Management LLC now owns 209 shares of the medical instruments supplier's stock valued at $55,000 after purchasing an additional 177 shares during the last quarter. Assetmark Inc. boosted its position in Insulet by 1,447.1% during the fourth quarter. Assetmark Inc. now owns 263 shares of the medical instruments supplier's stock valued at $69,000 after purchasing an additional 246 shares during the last quarter. Coppell Advisory Solutions LLC boosted its position in Insulet by 135.0% during the fourth quarter. Coppell Advisory Solutions LLC now owns 282 shares of the medical instruments supplier's stock valued at $74,000 after purchasing an additional 162 shares during the last quarter. Finally, MassMutual Private Wealth & Trust FSB boosted its position in Insulet by 23.1% during the first quarter. MassMutual Private Wealth & Trust FSB now owns 314 shares of the medical instruments supplier's stock valued at $82,000 after purchasing an additional 59 shares during the last quarter.

Analysts Set New Price Targets

PODD has been the subject of a number of recent analyst reports. Raymond James Financial reaffirmed an "outperform" rating and issued a $360.00 price objective (up from $328.00) on shares of Insulet in a research report on Tuesday, May 27th. Wells Fargo & Company set a $322.00 price objective on Insulet in a research report on Monday, April 28th. Citigroup reaffirmed a "buy" rating on shares of Insulet in a research report on Tuesday, July 8th. Wolfe Research raised Insulet from a "peer perform" rating to an "outperform" rating and set a $350.00 price objective for the company in a research report on Tuesday, May 13th. Finally, Sanford C. Bernstein reaffirmed an "outperform" rating on shares of Insulet in a research report on Friday, May 16th. Four equities research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company's stock. According to data from MarketBeat.com, Insulet has an average rating of "Moderate Buy" and an average price target of $321.00.

Insulet Price Performance

NASDAQ PODD traded down $8.08 during midday trading on Friday, hitting $289.32. The company had a trading volume of 507,503 shares, compared to its average volume of 721,324. The company has a market capitalization of $20.36 billion, a PE ratio of 52.04, a P/E/G ratio of 2.58 and a beta of 1.35. The company has a current ratio of 4.47, a quick ratio of 3.63 and a debt-to-equity ratio of 1.21. The firm has a 50-day moving average price of $307.29 and a 200-day moving average price of $280.25. Insulet Corporation has a twelve month low of $173.00 and a twelve month high of $329.33.

Insulet (NASDAQ:PODD - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The medical instruments supplier reported $1.02 earnings per share for the quarter, beating the consensus estimate of $0.81 by $0.21. The firm had revenue of $569.00 million during the quarter, compared to analysts' expectations of $543.20 million. Insulet had a return on equity of 22.25% and a net margin of 18.29%. The company's quarterly revenue was up 28.8% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.73 EPS. As a group, analysts anticipate that Insulet Corporation will post 3.92 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Insulet news, SVP John W. Kapples sold 5,278 shares of Insulet stock in a transaction on Wednesday, May 14th. The stock was sold at an average price of $318.47, for a total value of $1,680,884.66. Following the completion of the transaction, the senior vice president directly owned 23,180 shares of the company's stock, valued at $7,382,134.60. The trade was a 18.55% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.39% of the stock is owned by corporate insiders.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.